AI Article Synopsis
- Posaconazole is used to prevent invasive pulmonary aspergillosis (IPA), but it has limitations due to drug interactions and side effects.
- PTX3 is a glycoprotein that enhances innate immunity and has shown protective effects in animal models of IPA.
- The study found that combining PTX3 with lower doses of posaconazole creates a synergistic effect, potentially offering a more effective treatment option with fewer risks.
Article Abstract
Posaconazole is currently used for the prophylaxis of invasive pulmonary aspergillosis (IPA). Limitations to posaconazole usage are drug-drug interactions and side effects. PTX3 is an innate immunity glycoprotein with opsonic activity, proven to be protective in IPA animal models. This study investigated the combination of posaconazole with PTX3. The results indicate synergy between PTX3 and posaconazole against aspergillosis, suggesting that a combination of reduced doses of posaconazole with the immune response enhancer PTX3 might represent a treatment option with a higher therapeutic index than posaconazole.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187902 | PMC |
| http://dx.doi.org/10.1128/AAC.03038-14 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!